1683-P: Fracture Risk Associated with Tirzepatide: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Evidence
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1683-p ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von FAROUQ B.F. ALAHMED und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: The impact of tirzepatide is substantial in reducing glucose and body weight, but its relevance to skeletal safety remains unknown. The purpose of this analysis is to evaluate the fracture risk of tirzepatide compared with controls in randomized trials and GLP-1 receptor agonists in real-world data.
Methods
We searched systematically for randomized phase 2/3 trials that reported fracture outcomes and comparative observational studies. For the analyses involving trials, the tirzepatide dose groups were combined to avoid double-counting. We combined results with fixed-effect Peto odds ratios for rare events and hazard ratios estimated by inverse variance in the observational study. PROSPERO: CRD420261278843.
Results
Eleven trials (N=10,240; tirzepatide n=6,357; control n=3,883) reported 50 fractures (37 vs 13; 0.58% vs 0.33%). Tirzepatide was associated with higher fracture odds (Peto OR 1.84, 95% CI 1.02-3.31; I2=25%; p=0.04). The retrospective study comparing tirzepatide with GLP-1 receptor agonists found no significant difference (HR 1.16, 95% CI 0.89-1.52; p=0.28).
Conclusion
There were a few fractures in total. Pooled-data analysis in RCTs yielded an increased odds ratio for fractures in the tirzepatide group compared to the control groups, whereas real-world analyses did not reveal a significantly increased risk. More long-term studies, as well as fracture outcome studies, would be desirable. Disclosure F.B. Alahmed: None. H. Alahmed: None. L.Z. Khan: None.
Zitieren
APA
ALAHMED, F. B., ALAHMED, H., & KHAN, L. Z. (2026). 1683-P: Fracture Risk Associated with Tirzepatide: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Evidence. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1683-p
Vancouver
ALAHMED FB, ALAHMED H, KHAN LZ. 1683-P: Fracture Risk Associated with Tirzepatide: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Evidence. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1683-p
BibTeX
@article{ALAHMED2026,
author = {ALAHMED, FAROUQ B.F. and ALAHMED, HOOR and KHAN, LEILA Z.},
title = {1683-P: Fracture Risk Associated with Tirzepatide: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Evidence},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1683-p}
}
EUVIMED